🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Cipla Limited CIPLA NIFTY50NSEAIPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.cipla.com

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

READ MORE ›
₹1,401.00
-4.13% 1Y

Market & Price

Market Cap
₹1.13 L Cr
Current Price
₹1,401.00
High / Low (52W)
₹1,663.60 / ₹1,192.40
Beta
0.09

Valuation

Stock P/E
29.16
Industry PE
37.60
Forward P/E
22.17
PEG Ratio
-
Book Value
₹407.53
Price to Book
3.44
P/S
4.08
EV/EBITDA
17.46
Dividend Yield
0.93%

Profitability & Returns

ROCE
14.88%
ROE
11.74%
ROA
7.38%
Profit Margin
14.00%
Op Margin
9.50%
EPS (Latest Qtr)
₹6.86
EPS (TTM)
₹48.05

Balance Sheet & Liquidity

Debt/Equity
1.78
Quick Ratio
2.08
Current Ratio
3.44
Debt
₹613.77 Cr
Total Assets
₹42,495.98 Cr
Current Assets
₹24,147.03 Cr
Working Capital
₹17,133.44 Cr

Ownership

Promoter Holding
34.57%
Chg in Prom Hold
-
FII / Inst Holding
44.22%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹1.03 L Cr
Total Revenue (TTM)
₹27,711.69 Cr
EBITDA
₹5,924.92 Cr
Free Cash Flow
₹142.89 Cr
Operating Cash Flow
₹3,940.02 Cr
Shares Outstanding
₹80.78 Cr
Gross Margin
65.54%
Payout Ratio
27.08%

Growth (CAGR)

Revenue 5Y
7.23%
Profit 5Y
11.45%
Revenue (YoY)
-3.80%
Earnings (YoY)
-54.60%

PROS

  • Profit CAGR of 11.5% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
6 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
7 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
8 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 965.10 65.34 ₹93,927.75 Cr 0.16% 12.70% 14.33% 23.10% 9.34%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue -6,961.60 Cr6,597.72 Cr6,837.04 Cr6,962.97 Cr6,464.26 Cr
Cost of Revenue -2,264.08 Cr2,189.02 Cr2,170.71 Cr2,632.08 Cr2,248.68 Cr
Gross Profit -4,697.52 Cr4,408.70 Cr4,666.33 Cr4,330.89 Cr4,215.58 Cr
Operating Expenses -2,988.40 Cr3,179.84 Cr3,140.91 Cr3,354.18 Cr3,601.53 Cr
Operating Income -1,709.12 Cr1,228.86 Cr1,525.42 Cr976.71 Cr614.05 Cr
EBITDA -2,210.53 Cr1,827.05 Cr2,036.70 Cr1,185.49 Cr1,103.11 Cr
Interest Expense -14.64 Cr14.02 Cr14.05 Cr14.03 Cr13.13 Cr
Pretax Income -1,916.09 Cr1,504.30 Cr1,769.93 Cr893.11 Cr707.06 Cr
Tax Provision -332.37 Cr279.28 Cr477.88 Cr218.55 Cr156.95 Cr
Net Income -1,570.51 Cr1,221.84 Cr1,297.62 Cr675.80 Cr554.64 Cr
Diluted EPS -19.4315.1216.068.366.86

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -22,473.18 Cr25,446.63 Cr27,145.40 Cr27,711.69 Cr
Cost of Revenue -8,960.63 Cr9,592.38 Cr8,928.99 Cr9,549.11 Cr
Gross Profit -13,512.55 Cr15,854.25 Cr18,216.41 Cr18,162.58 Cr
Operating Expenses -9,494.68 Cr10,485.59 Cr12,195.46 Cr13,448.64 Cr
Operating Income -4,017.87 Cr5,368.66 Cr6,020.95 Cr4,713.94 Cr
EBITDA -5,152.10 Cr6,824.05 Cr7,989.77 Cr6,489.00 Cr
Interest Expense -94.56 Cr71.13 Cr62.01 Cr54.39 Cr
Pretax Income -4,038.35 Cr5,701.90 Cr6,820.81 Cr5,223.63 Cr
Tax Provision -1,202.86 Cr1,546.59 Cr1,529.76 Cr1,353.84 Cr
Net Income -2,801.91 Cr4,121.55 Cr5,272.52 Cr3,879.23 Cr
Diluted EPS 31.1734.6951.0165.24-

Compounded Sales Growth

5 Years:7.23%
1 Year:-3.80%

Compounded Profit Growth

5 Years:11.45%
1 Year:-54.60%

Stock Price Performance

1 Year:-4.13%
6 Months:-7.06%
3 Months:+5.60%
1 Month:+6.98%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -29,463.28 Cr32,717.82 Cr37,387.04 Cr42,495.98 Cr
Current Assets -17,274.95 Cr19,441.41 Cr23,288.52 Cr24,147.03 Cr
Cash & Equivalents -627.63 Cr640.07 Cr588.69 Cr1,018.22 Cr
Inventory -5,156.43 Cr5,237.95 Cr5,642.11 Cr6,596.72 Cr
Receivables -4,057.00 Cr4,770.66 Cr5,506.37 Cr5,620.05 Cr
Total Liabilities -5,749.74 Cr5,915.49 Cr6,097.79 Cr7,975.74 Cr
Current Liabilities -5,109.67 Cr5,245.77 Cr5,483.96 Cr7,013.59 Cr
Long Term Debt -0011.98 Cr117.47 Cr
Total Debt -803.12 Cr559.41 Cr438.19 Cr613.77 Cr
Total Equity -23,407.78 Cr26,706.43 Cr31,193.45 Cr34,431.95 Cr
Shares Outstanding -80.72 Cr80.74 Cr80.76 Cr80.78 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -3,237.65 Cr4,133.91 Cr5,004.98 Cr3,940.02 Cr
Investing Cash Flow --2,388.51 Cr-2,988.03 Cr-3,691.14 Cr-2,326.13 Cr
Financing Cash Flow --958.29 Cr-1,200.43 Cr-1,292.79 Cr-1,233.65 Cr
Capital Expenditure --1,182.89 Cr-1,349.30 Cr-1,548.20 Cr-3,079.31 Cr
Free Cash Flow -2,054.76 Cr2,784.61 Cr3,456.78 Cr860.71 Cr
Net Change in Cash --109.15 Cr-54.55 Cr21.05 Cr380.24 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -60.1%62.3%67.1%65.5%
Operating Margin % -17.9%21.1%22.2%17.0%
Net Margin % -12.5%16.2%19.4%14.0%
ROE % -12.0%15.4%16.9%11.3%
ROCE % -16.5%19.5%18.9%13.3%

Shareholding Pattern

Insiders
34.57%
Institutions
44.22%
Public Float
67.59%

Top Institutional Holders

#Holder% HeldSharesValue
1 Vanguard International Stock Index-Emerging Markets Stk 0.89% 72.09 L ₹1,009.99 Cr
2 Vanguard International Stock Index-Total Intl Stock Indx 0.82% 66.30 L ₹928.86 Cr
3 Advisors Inner Circle Fund III-GQG Partners Emerging Markets Equity Fd 0.62% 50.33 L ₹705.10 Cr
4 iShares Core MSCI Emerging Markets ETF 0.54% 43.28 L ₹606.39 Cr
5 Hartford/Schroders Emerging Markets Equity Fd 0.37% 30.16 L ₹422.59 Cr
6 iShares MSCI Emerging Markets ETF 0.24% 19.61 L ₹274.78 Cr
7 DFA Emerging Markets Core Equity Portfolio 0.20% 15.99 L ₹223.99 Cr
8 Fidelity SAI Emerging Markets Low Volatility Index Fund 0.18% 14.31 L ₹200.47 Cr
9 Mercer Emerging Markets Equity Fd 0.15% 11.79 L ₹165.16 Cr
10 Driehaus Emerging Markets Growth Fund 0.14% 11.27 L ₹157.91 Cr

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CIPLA

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space